MOLECULAR PARTNERS AG -ADR (MOLN) Stock News

USA - NASDAQ:MOLN - US60853G1067 - ADR

3.67 USD

-0.1 (-2.65%)

Last: 9/22/2025, 8:46:46 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MOLN Latest News, Press Relases and Analysis

All

Press Releases

21 days ago - By: Benzinga

Looking Into Molecular Partners's Recent Short Interest

a month ago - By: Benzinga - Mentions: EPIX LPTX NBTX FEMY ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

a month ago - By: Molecular Partners

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

a month ago - By: Molecular Partners

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

a month ago - By: Molecular Partners

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

a month ago - By: Molecular Partners

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

3 months ago - By: Molecular Partners

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

3 months ago - By: Molecular Partners

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

3 months ago - By: Molecular Partners

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

3 months ago - By: Molecular Partners

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

4 months ago - By: Molecular Partners

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

4 months ago - By: Molecular Partners

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

4 months ago - By: Molecular Partners

Molecular Partners to Present at Upcoming Investor Conferences

4 months ago - By: Molecular Partners

Molecular Partners to Present at Upcoming Investor Conferences

4 months ago - By: Molecular Partners

Molecular Partners Reports Financial Results and Highlights from Q1 2025

4 months ago - By: Molecular Partners

Molecular Partners Reports Financial Results and Highlights from Q1 2025

5 months ago - By: Molecular Partners

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

5 months ago - By: Molecular Partners

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

5 months ago - By: Molecular Partners

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

5 months ago - By: Molecular Partners

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

6 months ago - By: Molecular Partners

Molecular Partners to hold three poster presentations at AACR 2025

6 months ago - By: Molecular Partners

Molecular Partners to hold three poster presentations at AACR 2025

6 months ago - By: Molecular Partners

Molecular Partners Publishes Invitation to Annual General Meeting 2025

6 months ago - By: Molecular Partners

Molecular Partners Publishes Invitation to Annual General Meeting 2025

7 months ago - By: Molecular Partners

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

7 months ago - By: Molecular Partners

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

7 months ago - By: Molecular Partners

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

7 months ago - By: Molecular Partners

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

8 months ago - By: Molecular Partners

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference